DGAP-News: MOLOGEN AG / Key word(s): Change of Personnel
MOLOGEN AG appoints Walter Miller as new CFO
16.03.2016 / 08:30
The issuer is solely responsible for the content of this announcement.
—————————————————————————
Press release N 5/ 2016 of 03/16/2016
MOLOGEN AG appoints Walter Miller as new CFO
Berlin, 16 March 2016 – The Supervisory Board of biotechnology company
MOLOGEN AG (ISIN DE0006637200, Prime Standard of the Frankfurt Stock
Exchange: MGN) today appointed Walter Miller as member of the Executive
Board and new Chief Financial Officer (CFO) of MOLOGEN AG with effect from
1 April 2016.
Upon taking office, Walter Miller will have responsibility within the
company for Finance and Administration as well as the Risk Management,
Compliance and Corporate Governance departments.
Oliver Krautscheid, Chairman of the Supervisory Board at MOLOGEN AG,
explained: “We are delighted to welcome Mr. Miller on board. He is an
excellent Chief Financial Officer with experience and expertise in the
biotech and pharma industry. In addition to his skills acquired in
commercial roles, he also has extensive experience in licensing activities
and capital market related topics. As part of previous roles, he has also
overseen various financing transactions. His knowledge and experience will
make a decisive contribution to advancing MOLOGEN’s development from a
research-based biotech company to a biopharmaceutical product company.”
“I see this as an exciting new challenge. Taking forward a company like
MOLOGEN, with its promising drug candidates in development, requires a
solid organizational structure with a market and product focus. I
particularly look forward to working with the highly committed and
experienced MOLOGEN team, without whom the successful implementation of the
corporate strategy will not be possible”, said Walter Miller.
With more than 15 years of experience in the biotechnology and
pharmaceutical sector, Walter Miller has worked at both start-ups and
listed companies in Germany and abroad. He was most recently CFO on the
management team of Nuvisan GmbH, an international contract research
organization (CRO) and laboratory services provider. He was responsible for
Finance, Legal, Purchasing and IT at the company from June 2013. Prior to
joining Nuvisan, he held various managerial posts at the listed Santhera
Pharmaceuticals Group. As Vice President Finance & Commercial Operations,
initially in Germany as well as subsequently in Switzerland, he was also a
member of the Group’s management team. Walter Miller started his
professional career at ISRA VISION PARSYTEC in Aachen, Germany.
MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.
The cancer immunotherapy lefitolimod (MGN1703) is the company’s lead
product and best-in-class TLR9 agonist. Treatment with lefitolimod
(MGN1703) triggers a broad and strong activation of the immune system. Due
to this mechanism of action, lefitolimod (MGN1703) has the potential to be
applied to various indications. Lefitolimod (MGN1703) is currently being
developed for first-line maintenance treatment of colorectal cancer
(pivotal study) and small cell lung cancer (randomized controlled trial).
Furthermore, it is also being investigated in a phase I study in HIV and a
phase I combination study with the checkpoint inhibitor Yervoy(R)
(ipilimumab) is expected to start within the first half 2016.
MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat
diseases for which there is a high medical need.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA – Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
industry e.V. (VCI)
MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
MOLOGEN AG.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 – 30 – 84 17 88 – 38
Fax: +49 – 30 – 84 17 88 – 50
investor@mologen.com
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
—————————————————————————
16.03.2016 Dissemination of a Corporate News, transmitted by DGAP – a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
—————————————————————————
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News Service
—————————————————————————
445635 16.03.2016
